The four main drug classes that significantly reduce mortality in heart failure (HFrEF) are: ARNI/ACEi/ARB (Angiotensin Receptor-Neprilysin Inhibitors/ACE Inhibitors/ARBs), Beta-Blockers, Mineralocorticoid Receptor Antagonists (MRAs), and SGLT2 Inhibitors; these are often called the "four pillars" of therapy for improving survival and reducing hospitalizations.
BETA BLOCKERS
The beneficial effect of beta blockade in HFrEF has been documented for more than 40 years. Since 1975, data have shown that the use of bisoprolol, carvedilol, or sustained-release metoprolol succinate reduces morbidity and mortality in patients with HFrEF.
The current paradigm of sequential drug therapy recommends a multi-drug combination therapy upfront, including four “aces,” classes: beta-blocker, MRA, ARNI, and SGLT2i. ARNI: angiotensin receptor neprilysin inhibitors; MRA: mineralcorticoid receptor antagonists; SGLT2i: sodium-glucose-cotransporter 2 inhibitors.
In summary, the totality of evidence now suggests that patients with HFrEF should be treated early with a combination of the four drugs: an ARNI, beta-blocker, MRA, and SGLT2 inhibitor in order to benefit from substantial and sustained reductions of mortality, heart failure hospitalizations, and symptoms.
ACE inhibitors
(See Titrating Medications in Heart Failure). ACEIs prolong survival in patients with New York Heart Association Class II-IV HF; improve patient symptoms and exercise tolerance; and reduce hospitalisations for worsening HF.
Digoxin has an average rating of 5.8 out of 10 from a total of 17 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 35% reported a negative effect. Entresto has an average rating of 5.1 out of 10 from a total of 203 ratings on Drugs.com.
Cardiac arrest is the mode of demise in 30–50% of patients with heart failure and a reduced ejection fraction (HFrEF), and conversely, systolic dysfunction is a major risk factor for sudden cardiac death in the community.
Mineralocorticoid Receptor Antagonists
Alternatives to Entresto
Drugs that can make heart failure worse include:
Sacubitril/valsartan (Entresto®) has been touted as the new wonder drug for heart failure (HF). Sacubitril is a prodrug that is activated in man to sacubitrilat that inhibits the enzyme neprilysin, a neutral endopeptidase.
How does bisoprolol work? Bisoprolol is a type of medicine called a beta blocker. Like other beta blockers, bisoprolol works by changing the way your body responds to some nerve impulses, especially in the heart. It slows down your heart rate and makes it easier for your heart to pump blood around your body.
Entresto is taken twice a day, while Jardiance is taken once daily. Entresto is available as tablets or oral pellets, and it doesn't have a generic version. Jardiance is only available as a tablet and also lacks a generic version.
Surgery. Medicines are the main treatment for heart failure, but for some people surgery may help. Operations that can help with heart failure include: heart valve surgery.
Thus, specific agents and doses used in clinical trials in heart failure include captopril 150 mg daily, enalapril 20-40 mg daily, and lisinopril 20-40 mg daily. Other agents approved for the treatment of heart failure include fosinopril and ramipril (the latter for heart failure after acute myocardial infarction).
ACE inhibitors help your heart pump better, open up (dilate) and relax your blood vessels so blood can flow better throughout your body, manage your blood pressure, lower your risk of a heart attack and help prevent stress hormones from making your heart failure worse. ACE inhibitors include: Captopril (Capoten®).
Entresto has an average rating of 5.1 out of 10 from a total of 203 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 47% reported a negative effect. Metoprolol has an average rating of 5.7 out of 10 from a total of 666 ratings on Drugs.com.
The mainstay of medical treatment for patients with heart failure with reduced ejection fraction (HFrEF) are beta blockers (BB), angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB), and mineralocorticoid receptor antagonists (MRA).
Entresto can start lowering the risk of heart failure-related hospitalizations within 30 days of starting it. And studies suggest it may extend life expectancy by about 1.5 years compared to another heart failure medication called enalapril (Vasotec).
It is now not uncommon to see patients living for more than 20 years after a heart failure diagnosis.
End-stage heart failure symptoms
When that happens, you experience symptoms related to the poor circulation of blood: Shortness of breath or difficulty breathing. Edema (fluid buildup and swelling) in the legs, feet and torso. Irregular heartbeat.
Exercises to avoid if you have heart failure
It's important to avoid exercise that involves heavy weight-lifting, or holding your breath. Don't do any exercises that use your whole body as a weight, such as press-ups or planks. And be careful if you're getting in the pool.
Stage 3 congestive heart failure
You may also experience symptoms such as weak legs, swollen feet, legs and stomach,” explains Dr Hadjiphilippou.